Anika Therapeutics, Inc. — Q3 2023 Form 10-Q Summary
Business Context and Reporting Period
Anika is a global joint-preservation company focused on osteoarthritis pain management, regenerative solutions, sports medicine, and Arthrosurface joint technologies. The filing covers the unaudited three and nine months ended September 30, 2023, compared with the corresponding 2022 periods. The company reports one operating segment.
Key Financial Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|
| Revenue | $41.5 million | $40.3 million | $123.7 million | $116.6 million |
| Gross profit | $24.9 million | $22.8 million | $76.8 million | $69.4 million |
| Gross margin | 60% | 57% | 62% | 60% |
| Loss from operations | $(7.7) million | $(5.8) million | $(23.9) million | $(12.7) million |
| Net loss | $(6.6) million | $(4.2) million | $(19.7) million | $(10.0) million |
| Diluted loss per share | $(0.45) | $(0.29) | $(1.34) | $(0.68) |
| Operating cash flow | Not separately provided | Not separately provided | $(5.4) million | $3.9 million |
- Q3 revenue increased 3%; nine-month revenue increased 6% year over year.
- Q3 and nine-month gross profit increased primarily from revenue growth, favorable product mix, improved production volumes, and lower inventory reserves.
- Research and development expense increased 7% in Q3 and 23% for the first nine months, mainly due to regulatory requirements and development of the Integrity Implant System.
- Selling, general and administrative expense increased 17% in Q3 and 22% year to date. Q3 included a $4.5 million charge related to discontinuation of a software development project.
- Adjusted EBITDA was $4.7 million in Q3 and $9.7 million for the first nine months, compared with $4.1 million and $10.7 million, respectively, in 2022.
Revenue and Material Changes
| Product family | Q3 2023 revenue | Year-over-year change | 9M 2023 revenue | Year-over-year change |
|---|
| OA Pain Management | $24.9 million | 2% | $76.9 million | 11% |
| Joint Preservation and Restoration | $13.5 million | 14% | $39.6 million | 10% |
| Non-Orthopedic | $3.1 million | (22%) | $7.3 million | (34%) |
- Growth in Joint Preservation and Restoration reflected increased adoption of newer products and greater distributor focus.
- OA Pain Management growth reflected customer demand but was partly offset in Q3 by unfavorable U.S. strategic-partner ordering patterns.
- Non-Orthopedic revenue declined because of distributor-order timing and the end of life of certain legacy products.
- DePuy Synthes Mitek Sports Medicine represented 44% of Q3 revenue and 45% of nine-month revenue, creating significant customer concentration.
- Beginning in 2023, veterinary revenue was reclassified from OA Pain Management to Non-Orthopedic; prior periods were revised for presentation.
Cash, Liquidity, Debt, and Capital Allocation
- Cash and cash equivalents were $70.7 million at September 30, 2023, down from $86.3 million at December 31, 2022. Working capital was $128.7 million, compared with $141.6 million at year-end.
- Nine-month cash use consisted of $5.4 million from operations, $3.6 million for capital expenditures, and $6.7 million from financing activities. Cash declined by $15.7 million.
- The operating cash outflow was primarily affected by $8.5 million of payments for non-recurring costs related to the Parcus Medical arbitration settlement, shareholder activism, and other corporate costs.
- The company had no outstanding borrowings under its $75.0 million senior revolving credit facility and was in compliance with its terms. Subject to conditions, total commitments may be increased to $150.0 million.
- Lease liabilities totaled $27.3 million at September 30, 2023. The filing does not identify conventional funded debt outstanding.
- In April 2023, the company authorized a $20.0 million share repurchase program. It completed a $5.0 million accelerated share repurchase, receiving 188,029 shares in total, including 29,046 shares delivered in July.
Outlook, Commentary, Risks, and Unusual Items
- Management expects to continue investing in research and development, commercial infrastructure, and operations. It stated that cash on hand, expected operating cash flow, and credit availability should fund anticipated needs, but also noted that additional financing could be required if resources become insufficient.
- Management expects to launch the FDA-cleared Integrity Implant System in early 2024. Cingal is marketed internationally but is not approved for commercial use in the United States.
- Management expects an operating loss for 2023. A valuation allowance was recorded against U.S. deferred tax assets because management determined they were not more likely than not to be realizable.
- The company recorded a $3.3 million charge related to settlement of the Parcus Medical earnout arbitration and paid the amount in April 2023. The former unitholders had sought earnout payments of up to $60 million.
- Other 2023 non-recurring costs included approximately $3.0 million for shareholder activism and $4.5 million for discontinuation of a software development project. Management identified approximately $13.0 million of non-recurring SG&A costs for the first nine months.
- Inventory reserves increased to approximately $11.5 million from $9.9 million at December 31, 2022, while reported inventories increased to $43.7 million from $39.8 million.
- The company’s principal risks include product development and commercialization, FDA and foreign regulatory requirements, competition, dependence on key personnel and proprietary technology, customer concentration, inventory and demand risk, foreign currency exposure, and the ability to achieve profitable growth.
- Disclosure controls and procedures were not effective at September 30, 2023 because previously disclosed material weaknesses in internal control over financial reporting remained outstanding. Remediation efforts were in progress but were not complete.
Important Facts for Investors to Verify
- Whether the company can convert revenue growth and improved gross margins into positive operating and free cash flow after elevated R&D and commercial spending.
- The timing, adoption, regulatory status, and commercial contribution of the Integrity Implant System and other pipeline products.
- The sustainability of growth in OA Pain Management and Joint Preservation and Restoration, particularly given reliance on DePuy Synthes Mitek Sports Medicine.
- The extent to which non-recurring 2023 costs, software-project charges, inventory reserves, and shareholder-related expenses will recur.
- Progress toward remediation of the material weaknesses in internal controls.
- Available liquidity after the share repurchase program and the company’s ability to fund operations without additional financing.
- The filing’s MD&A contains an apparent typographical inconsistency for nine-month diluted loss per share; the financial statements report $(1.34), while one MD&A sentence appears to state $(0.29). Investors should rely on and verify the audited presentation and subsequent filings.
